Click here to read the article, featuring GfK researchers providing data-based insights into the potential of these new products.*

Looking ahead to 2018, the most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms.

That comes with a catch. Consumers are more sensitive than ever to high prices, with more than 30 states introducing legislation on drug pricing. Given the current political climate, the market is likely to place a premium on novel therapies that truly advance the standard of care. Indeed, next year's most promising late-stage candidates run the gamut, from drugs with never-before-seen mechanisms to old standbys with new potential.

The products featured in this pipeline report cover the following major areas:

  • Gene therapy
  • Immunology
  • Neurology
  • Oncology
  • Pain
  • Genetic disorders
  • Metabolic

Other key products in the pipeline cover genetic and/or multifactorial disorders, infectious disease, women's health and orphan.

GfK SE published this content on 08 December 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 08 December 2017 07:47:07 UTC.

Original documenthttp://www.gfk.com/insights/news/medical-marketing-and-medias-annual-feature/

Public permalinkhttp://www.publicnow.com/view/7397303A5E768DFF64C6EA0767B328C74BFEDEF7